An inhaler article includes a tubular housing defining a holder body extending along a longitudinal axis from a mouthpiece end to a consumable receiving end. The holder body includes an inner tube extending along the longitudinal axis and within the tubular housing from a tube intake end to a tube exhaust end. The tube intake end is proximate the consumable receiving end. The inner tube defines an air flow lumen with two or more air flow apertures extending through a wall of the inner tube. An air blocking feature is positioned in the air flow lumen and between two of the air flow apertures. A vibration inducing element disposed on the inner tube proximate to the tube exhaust end or the tube intake end, the vibration inducing element comprises an aperture through the wall of the inner tube and having a tapered or angled downstream aperture edge.

A delivery device for use in administering a dry powder to a biological subject's airway is provided. The device comprises (a) a housing having an inlet in fluid communication with an outlet for delivering a flow of gas to the subject's airway; and (b) one or more cantilever structures located within the housing. Vibration of the one or more cantilever structures facilitates entry of the dry powder into the flow of gas, such that the dry powder can be delivered by the flow of gas through the outlet to the subject's airway. Also provided is a container for releasably storing a particulate composition, the container comprising a shell sealed by a seal in which the particulate composition is stored, wherein a puncturing device for rupturing the seal to release the particulate composition is housed within the shell. Further provided are associated methods for administering dry powder using the delivery device and/or container.

A stable-foam inhalation-device cartridge for a stable-foam inhalation device which dispenses a stable foam to be consumed by a user. The cartridge is devoid of an electrical energisation component. The cartridge includes a flexible mixing chamber, first and second foam-generation elements, an expansion chamber, a partitioning element having one or more mixing members for agitating a consumable foam and a discharge element. The discharge element has an outlet opening an inlet opening and a discharge conduit which interconnects the inlet opening with the outlet opening. The discharge conduit has a longitudinal extent which locates the inlet opening at a position closer to the partitioning element than to the outlet opening.

The present invention provides for the integration of drug dispersion methods into a drug or medicine delivery system. The drug dispersion methods used include shear (e.g., air across a drug, with or without a gas assist), capillary flow or a venturi effect, mechanical means such as spinning, vibration, or impaction, and turbulence (e.g., using mesh screens, or restrictions in the air path). These methods of drug dispersion allow for all of the drug in the system to be released, allowing control of the dosage size. These methods also provide for drug metering, fluidization, entrainment, deaggragation and deagglomeration. The present invention also provides for the integration of a drug sealing system into the device. The drug sealing system provides a way of blocking the migration of drug from one area of the package to another. The drug seal system can also provide a method of tightly containing the drug until the package is opened, of directing airflow through the package and of managing and containing the drug during the package/device manufacturing process.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

A device for delivering medication to a user may include a main body, an electronics module, and a slider. The main body may include a mouthpiece, a medication reservoir, and a mouthpiece cover, where the mouthpiece cover may be hinged to the main body. The electronics module may include a communication circuit, a pressure sensor, and a switch. The slider may be configured to engage the switch when the mouthpiece cover moves from a closed position to an open position. The switch may be configured to switch the electronics module from an off state or a sleep state to an active state. The electronics module may be configured to never return to the off state after the mouthpiece cover is moved to expose the mouthpiece for the first time by the user.

A device for delivering an agent that includes a housing configured to store an agent and a cone assembly at least partially received within the housing. The cone assembly including an inner wall configured to be adjacent to the agent, an outlet channel extending from the inner wall, an inlet channel, and an intermediate channel between the outlet channel and the inlet channel. The inlet channel is in fluid communication with the outlet channel via the intermediate channel. The device includes a filter disposed within the inlet channel and positioned adjacent to the intermediate channel. The filter including a plurality of pores configured to permit a fluid received by the inlet channel to pass through the intermediate channel to mix with the agent adjacent to the inner wall.

Devices, systems, and methods are provided for adherence monitoring and patient interaction. In general, the devices, systems, and methods can facilitate a patient's adherence to a medication schedule and can facilitate monitoring and tracking of the patient's adherence to the medication schedule. In one embodiment, a medical accessory such as a cap is provided that can be configured to attach to existing medication dispensers, such as asthma inhalers, or to be integrated into a custom-made medication dispenser. The accessory can be configured to provide a notification to the patient when medication is due. The accessory can be configured to detect usage of the dispenser. The accessory can be configured to provide data regarding dispensing of the medication to an external device. The data can be analyzed and provided for visualization on a user interface.

The present invention provides a particulate delivery device with an automatic activation mechanism that pierces or cuts a composition capsule when a cap is removed. The cap cannot be replaced once the device is activated for use. The device allows for gas flow through the device from a gas inlet to a gas outlet through a composition receptacle and dispersion chamber to deliver particulate to the airway of a subject.

A medical device including an application device with a first fluid path and a container movably attached to the application device. The container and the application device have a second fluid path therethrough, the container includes an inner chamber that is intermediate proximal and distal portions of the second fluid path, the inner chamber is fluidly isolated from the proximal portion of the second fluid path at a first position of the container, and the inner chamber is fluidly coupled to the proximal and distal portions of the second fluid path at a second position of the container. The first fluid path bypasses the container and the passage of fluid through the first fluid path is separately controllable from the passage of fluid through the second fluid path.